If the stock price is any indication, it looks quite likely that Vertex will release some very positive result at the North American Cystic Fibrosis Conference in 2 weeks time on the trials that address the treatment of CFers with double F508del mutation. When Vertex announced top-line results in June, some investor hesitated about the clinical relevance of the 3.3% improvement in lung function. Those worries have apparently faded since Vertex management have been on the road this fall speaking at investor conferences and meeting with analysts and institutional investors. The 30% reduction in pulmonary exacerbations they are reporting in the studies is very significant and will be a highlight of the upcoming cystic fibrosis conference. Based on Vertex comments, investors are getting more bullish on Kalydeco/VX-809 pricing, which could come in above consensus and driving Vertex stock price up. So all signs point to a positive report on the Vertex double F508del mutation trials.
If you would like to read the source of this news go here:
http://t.co/tYMFbWGK3L
The article is a well written one that also covers the ProQR IPO launch last week and its relevance to Vertex.
Like, share and comment on our Facebook page: https://www.facebook.com/knowcf/pho...385540.257971313776/10152841357058777/?type=1
- Chris Baldwin
If you would like to read the source of this news go here:
http://t.co/tYMFbWGK3L
The article is a well written one that also covers the ProQR IPO launch last week and its relevance to Vertex.
Like, share and comment on our Facebook page: https://www.facebook.com/knowcf/pho...385540.257971313776/10152841357058777/?type=1
- Chris Baldwin